Overview

Atorvastatin as an Adjunct to DFDBA in Intrabony Defects

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:
0

Participant gender:
All

Summary

Periodontitis is a major oral health problem which leads to the progressive destruction of periodontal ligament and alveolar bone with pocket formation, recession or both. The ultimate goal of periodontal therapy is to regenerate the lost periodontal tissue. The most common form of regenerative periodontal therapy is the use of bone grafts which stimulate bone formation by the processes of osteoinduction and osteoconduction. Statins are a group of lipid lowering drugs which inhibit bone resorption by inhibition of the enzyme HMG-CoA reductase. They also stimulate new bone formation by local stimulation of BMP-2, a major bone growth regulatory factor. They also have anti-inflammatory and anti oxidant properties. Very few studies exist evaluating the beneficiary effects of grafts if combined with the statins which might enhance the regeneration by bone grafts. Hence, the present study was carried out in an attempt to comparatively evaluate clinically and radiologically, the efficacy of atorvastatin gel as an adjunct to allograft in the treatment of intrabony defects.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Kamineni Institute of Dental Sciences

Treatments:

Atorvastatin
Atorvastatin Calcium

Criteria

Inclusion Criteria:

1. Systemically healthy individual based on personal and medical history.

2. Presentation of untreated Chronic Periodontitis with intrabony defect having probing
pocket depth (PPD) ≥5mm or clinical attachment loss of ≥ 3mm and radiographic signs of
angular bone loss.

Exclusion Criteria:

1. Patients diagnosed and treated for systemic disease

2. Pregnant and Lactating women

3. Smokers

4. History of allergy to statin group or patients on systemic statin therapy.

5. History of antibiotic or periodontal therapy for the past 6 months.